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Abstract The discovery that histone deacetylase inhibitors
(HDACis) can attenuate acute kidney injury (AKI)-mediat-
ed damage and reduce fibrosis in kidney disease models has
opened the possibility of utilizing HDACis as therapeutics
for renal injury. Studies to date have made it abundantly
clear that HDACi treatment results in a plethora of molec-
ular changes, which are not always linked to histone acety-
lation, and that there is an essential need to understand the
specific target(s) of any HDACi of interest. New lines of
investigation are beginning to delve more deeply into target
identification of specific HDACis and to address the relative
toxicity of different HDACi classes. This review will focus
on the utilization of HDACis during kidney organogenesis,
injury, and disease, as well as on the development of these
compounds as therapeutics.
Keywords Histone deacetylase . HDACi . Kidney
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Introduction
Histone deacetylases (HDACs) play multiple roles during
both kidney development [1] and the pathogenesis of kidney
disease [2]. The continued development of isoform-selective
histone deacetylase inhibitors (HDACis) will provide the
scientific community with the necessary tools to study the
individual roles that HDACs play during these processes.
The goals of this review are to summarize what is currently
known about the requirements for specific HDACs during
renal development, and to address how the therapeutic ap-
plicability of HDACis has expanded beyond the field of
cancer and now applies broadly to the field of kidney
disease.
Acetylation and deacetylation of nucleosomal histone pro-
teins serves as a post-translation modification that regulates
transcriptional activity. This mechanism involves the interplay
between the activity of two enzyme classes: (1) histone ace-
tyltransferases (HATs), which promote an open chromatin
configuration and transcriptional activation, and (2) HDACs,
which generally promote chromatin condensation and tran-
scriptional repression. Specifically, most HDACs remove ace-
tyl groups from the ε-amino moiety of lysine residues located
on N-terminal histone tails. This leaves the histone with a net
positive charge, which strengthens its electrostatic interaction
with the DNA phosphate backbone and results in transcrip-
tional repression of associated genes.
As members of large multi-protein complexes, HDACs
also target many non-histone proteins [3] and, in some instan-
ces, participate directly in gene activation [4, 5]. For example,
HDACs positively regulate the oncogene c-Jun as well as the
anti-apoptotic gene Bcl-2 [5]. Additionally, it has been dem-
onstrated that HDACs are required for interferon-induced
gene expression, which is critical for an antiviral immunolog-
ical response [6]. Therefore, the function of HDACs, either as
corepressors or coactivators, appears to be context-dependent.
HDAC classes
To date, 18 mammalian HDAC proteins have been identi-
fied, and they are divided into four classes based on simi-
larity to yeast orthologs [7]. Class I, II, and IV enzymes
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depend on zinc for catalytic activity and contain a highly
conserved deacetylase domain [2, 8]. Class III enzymes,
which are not the focus of this review, are termed sirtuins.
They are structurally distinct from other HDAC classes
since the catalytic activity of these enzymes depends on
NAD+ rather than zinc and histones are not their primary
substrate [2, 8]. Class I is comprised of HDACs 1, 2, 3, and
8. Class II is subdivided into class IIa, containing HDACs 4,
5, 7, and 9, and class IIb, which contains HDACs 6 and 10.
HDAC 11 is the sole member of class IV because its
catalytic domain resembles the actives sites of both class I
and class II enzymes [8].
Understanding HDAC substrate specificity, as well as
identifying strategies for developing novel isoform-
selective HDACis, depends on thoroughly distinguishing
between and within HDAC classes (for a more in-depth
review, please see [2, 8, 9].) Class I HDACs are expressed
ubiquitously, are localized to the nucleus, and interact with
corepressor complexes to exert their function. HDAC1 and
HDAC2 are recruited to the NuRD (nucleosome remodeling
and deacetylation), Co-REST (corepressor for RE1 silenc-
ing transcription factor), and Sin3 corepressor complexes,
whereas HDAC3 is most often recruited to the SMRT/N-CoR
(silencing mediator for retinoid and thyroid receptors/nuclear
receptor corepressor) complex [10]. HDAC8 does not appear
to be recruited to corepressor complexes and is the only class I
HDAC with intrinsic enzymatic activity [11].
Class II HDACs are thought to have tissue-specific roles,
and are expressed in both the cytoplasm and the nucleus
[12]. Class IIa enzymes contain a mutation in the catalytic
site, resulting in a 1,000-fold reduction in activity [8].
Therefore alternative mechanisms, such as the recruitment
of class I HDACs [8] or the interaction with corepressor
complexes such as SMRT and N-CoR [10, 13], may be
required to achieve activity. It has been proposed that this
class of HDACs might act as “receptors” rather than
enzymes, since they often bind acetylated lysine residues
without actually performing the deacetylation reaction [14].
Additionally, a class IIb member, HDAC6 appears to pri-
marily target α-tubulin which may be a result of its unique
structure, consisting of two catalytic domains and a zinc
finger [15].
Available HDAC inhibitors
By preventing the removal of acetyl groups, HDAC inhibitors
provide transcriptional activators and repressors with greater
access to DNA resulting in altered gene expression patterns. In
the 1970s, sodium butyrate, a natural fatty acid produced by
bacteria, was one of the earliest HDAC inhibitors reported to
alter proliferation and gene expression in cell culture [16].
Approximately 20 years later, the antifungal agents trapoxin
and trichostatin A (TSA) were isolated from bacterial and
fungal sources, respectively [13]. These compounds were first
noted for their ability to induce cell cycle arrest and cancer cell
differentiation. It was later appreciated that these effects were
the result of histone modifications [13, 17].
HDAC inhibitors targeting class I and II HDACs gener-
ally follow a classic warhead-linker-cap structure (Fig. 1).
The warhead, or chelator, binds zinc in the HDAC catalytic
site, rendering the enzyme inactive. The linker is a carbon
chain that connects the warhead and cap and spans the
length of the HDAC pocket. The cap, or surface-binding
domain, interacts with residues on the surface of the HDAC
enzyme and contributes to isoform specificity of the inhib-
itor [14]. There are at least four categories of HDACis that
adhere to this structure: short chain fatty acids, hydroxamic
acids, aminobenzamides and cyclic peptides. The short
chain fatty acids are carboxylic acids that include valproic
acid (VPA), butyric acid, phenyl butyrate (PBA), and 4-
(phenylthio) butanoic acid (PTBA). These inhibitors are
relatively weak and display some class I specificity. The
hydroxamic acids are more broad-spectrum inhibitors capa-
ble of inhibiting class I and II HDACs, and include TSA,
suberoylanilide hydroxamic (SAHA), LBH-589, LAQ-824,
and PXD-101. Aminobenzamides are class I-selective and
include SNDX-275, MGCD0103, and MS-275. Finally, there
are several cyclic peptides, such as depsipeptide (romidepsin/
FK-228) and apicidin, which appear moderately selective for
class I HDACs [2, 17]. Although originally isolated as natural
compounds, several synthetic analogs have now been created
[18, 19].
The development of the first synthetic HDACi for thera-
peutic use in humans began somewhat serendipitously in the
1970s. It had been shown that dimethyl sulfoxide (DMSO)
Fig. 1 Characteristic design of histone deacetylases (HDAC) inhibi-
tors. The general structure of HDAC inhibitors can be broken into three
regions, each with a specific function: cap, linker, and warhead. Mod-
ifications can be introduced at each portion of the moiety, contributing
to structural diversity
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and other polar solvents could induce both differentiation
and growth arrest in cultured cancer cells [20]. Hypothesizing
that these molecules bound a metal ion in the HDAC active
site led to the production of compounds such as SAHA
(vorinostat), which possess a hydroxamic acid warhead and
therefore chelate zinc more efficiently [21, 22]. As with TSA,
SAHA inhibits class I and II HDACs, and was the first FDA-
approved HDAC inhibitor for the treatment of refractory
cutaneous T-cell lymphoma (CTCL) [17]. Due to their pro-
differentiation, anti-proliferative effects, HDACis have gener-
ated excitement in the cancer field as novel chemotherapeutic
agents [23, 24]. Since SAHA, about a dozen other compounds
have entered clinical trials [14] (See Table 1) and, in 2009, the
FDA also approved FK-228 (romidepsin), for treatment of
CTCL [25]. Currently, SAHA and romidepsin are the only
two FDA-approved HDAC inhibitors.
Toxicities and limitations of HDACi therapy
The HDACi literature suggests that compounds have differ-
ential and even paradoxical effects in cancer cells as com-
pared to non-cancerous cells. Whereas HDAC inhibition is
anti-proliferative in cancer cells, it can convey pro-
proliferative signals in developmental settings [26]. In addi-
tion, HDACis are highly toxic to cancer cells yet appear to
have cytoprotective effects in non-cancerous cells [2]. In
fact, non-cancerous cells are much more resistant to high
HDACi doses than cancer cells, and low doses have actually
been shown to be both reno- [27, 28] and neuroprotective
[29, 30]. One possible mechanism for differential sensitivity
to SAHA treatment has been related to the availability of
ROS scavenging proteins. SAHA treatment results in the
upregulation of TBP-2 levels and a subsequent decrease in
availability of ROS scavenging proteins. This effect, in
combination with SAHA’s ability to cause increased ROS
generation in cancer cells, may lead to preferential cancer
cell death [17].
Despite apparent cytoprotective effects in some cell types,
there is also evidence of cytotoxicity in non-cancerous cells
following HDACi treatment. SAHA was shown to induce
apoptosis in 35 % of a population of cultured rat renal prox-
imal tubule cells [31]. In culturedmouse proximal tubule cells,
TSA treatment resulted in the upregulation of the mitochon-
drial adapter protein p66sch. This increase is presumably
linked to ROS generation since knockdown of p66sch atten-
uated ROS production in treated cells [32]. In general,
hydroxamic acids, such as SAHA and TSA, are subject to
modification via sulfation, which leads to the buildup of
highly reactive, toxic sulfate metabolites of the hydroxy group
[33]. For this reason, the therapeutic potential of TSA may be
limited, even though it is widely used for research purposes.
Table 1 Human clinical trials involving HDAC inhibitor therapies to
treat renal cancer. Numerous HDACis have entered clinical trials as
monotherapy and as combination therapy for the treatment of RCC. To
date, only two HDACis have been approved by the Federal Food and
Drug Administration, vorinostat and romidepsin. Keywords: Histone
deacetylase, HDACi, kidney development, kidney regeneration, renal
injury, and renal disease. For additional information on HDAC inhib-
itors in clinical trials in other cancer types, see clinicaltrials.gov or :
www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/
default.htm
HDACi class Compound Combination therapy Clinical status Major therapeutic target References
Benzamides Entinostat (MS-275) Aldesleukin (Interleukin 2) Phase I/II Metastatic RCC a
13-cis-retinoic acid Phase I RCC and other
solid tumors
[105]
Cyclic tetrapeptides Romidepsin (FK228,
depsipeptide)
Monotherapy Phase II Metastatic RCC a, [113]




Bevacizumab (VEGF inhibitor) Phase I/II Metastatic RCC a
13-cis-retinoic acid Phase I/II Advanced RCC a
SB-715992 Phase II Advanced RCC
Ridaforolimus (mTOR inhibitor) Phase I Advanced RCC a
Sorafenib Phase I RCC and other
solid tumors
a, [114]
Panobinostat (LBH589) Monotherapy Phase II Refractory Clear
Cell RCC
a, [115]
Sorafenib Phase I Advanced RCC a
Everolimus (mTOR inhibitor) Phase I/II Metastatic RCC a
Short chain fatty acids Valproic acid Monotherapy Phase I Pediatric solid tumors [116]
a clinicaltrials.gov
HDAC histone deacetylase, RCC renal cell carcinoma, VEGF vascular endothelial growth factor, mTOR mammalian target of rapamycin
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Based on these studies, it may be warranted to monitor renal
function in patients undergoing HDACi therapy, particularly if
the treatment regimen involves those classes found to have
cytotoxic effects.
From a global perspective, patients tolerate HDACi ther-
apy quite well, and the maximum tolerated dose has yet to
be reached in some regimens [24]. Common side-effects of
SAHA, romidepsin, and MS-275 include fatigue, nausea,
and vomiting, although these are reversible upon treatment
withdrawal [17, 24]. More worrisome, however, are the
cardiac and immunologic effects, such as QT prolongation,
thrombocytopenia, and/or myelosuppression, following
HDACi treatment. Specifically, QT prolongation was ob-
served during clinical trials with romidepsin, although con-
founding factors were also identified in specific patient
populations [25] (See [24] for a more in-depth review of
specific side-effects associated with individual HDAC
inhibitors.) Additionally, valproic acid is a teratogen known
to cause neural tube and other birth defects [34]. Although
one study determined that TSA administered to pregnant
mice did not harm either the mothers or the pups, further
studies are warranted to examine the effects of HDACis
during embryonic development [35].
One hypothesis for decreasing these toxicities includes the
use of isoform-specific HDACis, rather than pan-inhibitors
like SAHA and romidepsin [2]. To make this feasible, a
viable, high-throughput assay testing isoform selectivity of
novel compounds is necessary. Bradner et al. have developed
an elegant kinetic assay for HDACs 1 through 9, which has
been validated by profiling 20 known HDAC inhibitors cur-
rently being used in either research or clinical settings [14].
This provides both researchers and clinicians with valuable
information about the precise isoform selectivity of com-
pounds so that mechanistic and off-target effects can be
evaluated.
HDACs and HDACi in kidney development
Many laboratories have contributed to the current under-
standing of the roles of HDACs during embryonic develop-
ment (for a good review see [9]). Initial studies have focused
on knockout mice where the function of a single HDAC has
been completely abrogated. Interestingly, these mice display
a myriad of phenotypes. For ubiquitously expressed HDACs
[8], such as HDAC1 and HDAC3, knockout results in early
embryonic lethality [36–39]. For those HDACs that display
tissue-specific expression, loss of function is generally more
tolerated. For example, HDAC5 and HDAC9 knockout
mice are both viable although they develop stress-induced
myocardial hypertrophy [40, 41].
In addition to these more general requirements for
HDACs during development, investigators are interested in
understanding the role that these enzymes play in organo-
genesis. In the mouse, HDAC4 regulates the extent of
chondrocyte hypertrophy, by inhibiting the activity of the
runt-related transcription factor-2 (Runx2), and therefore is
critical for skeletogenesis [42]. In the zebrafish, both Hdac1
and Hdac3 have been studied in detail. Interestingly, hdac1
mutants and morphants proceed through early development
without complication [43]. However, by 48 h post-fertilization
(hpf), edema is apparent and circulation has been compro-
mised. There is an absence of craniofacial cartilage structures
as well as a reduction in the development of the pectoral fins.
Retinal disorganization is also observed, and a requirement for
Hdac1 in cell cycle exit and subsequent differentiation of
retinal progenitors has been shown [43, 44]. Additionally,
specification and differentiation of the liver and exocrine
pancreas are severely delayed in hdac1 mutants owing to
reduced proliferation within the endoderm [45, 46]. Treatment
of zebrafish embryos with non-teratogenic levels of valproic
acid, a class I-specific HDACi, phenocopies hdac1 mutants
[46]. Interestingly, rescue of reduced liver size can be
achieved by injection of hdac3 mRNA as opposed to hdac1
mRNA, suggesting an additional requirement for Hdac3 in
zebrafish liver development.
Recently, data from both zebrafish and mice have impli-
cated HDACs in the development of the pronephric and
metanephric kidneys, respectively. In the zebrafish, specifi-
cation of renal progenitor cells within the intermediate me-
soderm occurs by 12 hpf. Over the course of the next 36 h,
these progenitor cells epithelialize, the nephron is patterned,
and a blood supply is delivered such that the pronephros
becomes the functional larval kidney [47]. Treatment of zebra-
fish embryos, beginning at approximately 2 hpf, with the
HDACis PTBA, PBA, or TSA results in an increase in renal
progenitor cell number [26]. This increase is proliferation-
dependent, since treatment with hydroxyurea and aphidicolin
abolishes the ability of PTBA to expand the progenitor cell
field. It is also dependent on functional retinoic acid (RA)
signaling. Interestingly, ectopic activation of the RA pathway
in both zebrafish and Xenopus results in the expansion of the
kidney field [48, 49], and inhibition of HDACs lowers the
threshold of RA required to activate transcription [50]. This
expansion of the kidney field, following treatment with
PTBA, persists throughout development and ultimately com-
promises kidney function due to renal progenitor cell hyper-
plasia [26], reminiscent of the teratogenic effects that have
been described for HDACis in the developing invertebrate and
vertebrate embryo [50]. Therefore, tight regulation of HDAC
activity in the early zebrafish embryo is required for both the
control of RA-dependent transcription and proliferation as
well as for the development of a functional pronephros.
Metanephric kidney development, which is preceded by
the development and degeneration of the pronephric and
mesonephric kidneys, begins with an outgrowth, known as
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the ureteric bud (UB), from the caudal end of the Wolffian
duct into the surrounding metanephric mesenchyme (MM)
[51, 52]. Reciprocal interactions between the UB and MM
result in branching and nephron induction, respectively.
Branching occurs in a very stereotypical pattern and ulti-
mately contributes to the collecting system, which includes
the collecting ducts, renal pelvis, and ureter. At the tips of each
branch, cells of the MM condense and begin their transition
from amesenchymal to an epithelial cell fate. They first form a
renal vesicle, which is spherical in shape and attached at one
end to the UB. Subsequently, single clefts are formed within
this vesicle, giving rise to the comma-shaped and then S-
shaped body. The S-shaped body is patterned along its
proximal-distal axis such that the distal end fuses with the UB
to form one continuous tubule and the proximal end develops
into the glomerulus, following invasion by endothelial cells.
Although there is a significant amount of data describing
the function of individual HDACs during organogenesis,
little is known about their specific roles during metanephric
kidney development. To address this deficiency, one group
has characterized the expression patterns of all class I and II
HDACs within the mouse kidney. HDACs 1-4, 7, and 9
appear to be temporally and to some extent spatially regu-
lated such that expression levels are at their peak within the
embryo and steadily decline as the mouse matures [1]. In
E13.5 and 15.5 kidneys, HDAC1, and its binding partner
HDAC2, localize to the undifferentiated and condensing
MM as well as to the nephron progenitors of the comma-
and S-shaped bodies [1, 53]. Interestingly, both are also
found within the UB branches. While this localization pat-
tern persists in postnatal mice, at a time when new nephrons
are being formed, the levels of these HDACs are signifi-
cantly reduced in more differentiated structures [1, 53]. A
similar expression pattern is shared by HDAC3 but, in
addition, this HDAC is also localized to the glomerular
podocytes [1, 53]. To determine the general function of all
class I and II HDACs during metanephric development,
E13.5 kidneys are either cultured with Scriptaid, an inhibitor
of class I and II HDACs, or its inactive analog Nullscript,
and RNA isolated from these samples is subjected to
genome-wide microarray analysis [1]. Many genes are
deregulated following HDACi treatment, including those
involved in Wnt/β-catenin, TGF-β/Smad, and PI3K-Akt
signaling [1, 54]. Transcription factors that promote MM
induction and survival, such as Eya1, Pax2, WT1, and
Emx2, are among the most sensitive, showing reduced ex-
pression levels after only two hours of treatment [1]. This
transcriptional deregulation has a significant impact on the
development of the metanephros. Following Scriptaid treat-
ment, kidneys appear hypoplastic with reduced UB branch-
ing, reduced proliferation, and increased apoptosis. Thus,
high HDAC activity in the metanephric kidney is critical for
promoting cell survival through transcriptional regulation.
While these data demonstrate that HDACs are essential for
kidney organogenesis, it does not address the differential
roles that individual HDACs play during this process. To
this end, work from another group suggests that the regulated
expression of HDACs and their downstream targets is re-
quired for kidney development to proceed in a controlled
manner. The renin-angiotensin system (RAS) promotes UB
branching through the repression of Sprouty, an inhibitor of
GDNF/Ret signaling [55]. Interestingly, treatment of E12.5
kidneys with exogenous Angiotensin-II, the principal growth
factor of the RAS, results in increased levels of HDAC1,
which promotes Sprouty expression [56]. Therefore, it appears
that tight regulation of Sprouty levels, achieved bymodulating
HDAC1 activity, is required for proper branching of the
ureteric bud during kidney morphogenesis. Taken together,
these data highlight the importance of epigenetic regulation
during metanephric kidney development.
HDACi in kidney disease and injury
Whether it involves tubular epithelial cells that lead to cyst
formation in polycystic kidney disease or glomerular epi-
thelial and mesangial cells leading to glomerulosclerosis,
the pathogenesis of many kidney diseases is characterized
by dysregulation of cellular proliferation, leading to fibrosis.
Since HDAC inhibition has been shown to be anti-fibrotic in
the lung, liver, and skin [35], it should not be surprising that
HDACis have been shown to have anti-fibrotic effects in
models of acute and chronic kidney disease.
HDACs were first implicated in the pathogenesis of non-
cancerous kidney disease in 2003, when Mishra et al. dem-
onstrated that TSA decreased proteinuria and the prolifera-
tive hallmarks of glomerulonephritis associated with SLE-
induced lupus in mice [57]. Although this group was initial-
ly interested in the anti-inflammatory effects of HDACis,
they recognized their anti-proliferative effects in some cell
populations. Since 2003, HDACis have been investigated
for their anti-fibrotic and anti-inflammatory effects in renal
disease [2], and there is emerging evidence that HDACis
may play a role in promoting tissue regeneration after acute
kidney injury. We will discuss the anti-fibrotic and anti-
inflammatory effects of HDACis in the context of various
models of kidney disease, as well as their pro-regenerative
effects following renal injury (summarized in Fig. 2).
Glomerular disease
Diabetic nephropathy
Although often clinically silent, renal hypertrophy (enlarged
kidney) is one of the earliest features of diabetic nephropathy.
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This may precede podocyte loss that leads to proteinuria.
Renal hypertrophy is associated with glomerular hyper-
filtration, which is thought to be an underlying mechanism
promoting progressive renal injury in diabetic nephropathy.
Although the underlying mechanisms promoting renal hyper-
trophy are complex, there is evidence that this results from
activation of mammalian target of rapamycin (mTOR) signal-
ing in the diabetic kidney [58]. Two studies have demonstrat-
ed that SAHA can attenuate renal hypertrophy in rodent
models of streptozotocin-induced diabetes [59, 60]. Advani
et al. found that SAHA treatment decreasedmouse kidney size
after 18 weeks compared to controls [59], and Gilbert et al.
similarly demonstrated that a 4-week SAHA course resulted
in attenuation of renal hypertrophy in rats [60]. While the
mechanism by which HDACi reduces renal hypertrophy in
this model is unknown, this group observed a decrease in
apoptosis in SAHA-treated kidneys, indicating that HDACi
treatment does not reduce kidney size via cellular toxicity.
Diabetic nephropathy is also characterized by glomerular
sclerosis resulting from excess deposition of matrix in the
glomerular mesangium, and loss of glomerular epithelial
cells, followed by aberrant fibrosis within the glomerular
structure. There is a substantial body of evidence to suggest
that this mechanism is mediated by activation of TGF-β
signaling in the diabetic glomerulus [61–63]. TGF-β1 has
been shown to upregulate HDAC2 in rodent models of dia-
betes, and treatment with nonselective or class I-selective
HDACis prevents fibrosis [64]. Additionally, HDAC2 knock-
down in cell culture decreased the accumulation of extracel-
lular matrix components, further implicating HDAC2 in
fibrosis. Thus, class I inhibition, and in particular HDAC2
inhibition, seems to have therapeutic potential in attenuating
the fibrotic features of diabetic nephropathy. Finally, oxidative
stress is also thought to play a role in regulating diabetic
nephropathy fibrosis [56]. Noh et al. observed that H2O2, a
potent inducer of oxidative stress, stimulated an increase in
HDAC2 levels [64]. SAHA treatment, however, decreased
markers of oxidative damage in the kidneys of diabetic mice
[59]. These studies indicate a key role for HDACis in attenu-
ating oxidative damage and fibrosis in diabetic nephropathy.
Glomerulonephritis
HDACi treatment has shown promise in several models of
glomerulonephritis. Nephrotoxic serum nephritis (NTN) is a
rat model characterized by the development of an aggres-
sive, proliferative, crescentic glomerulonephritis giving rise
to progressive glomerulosclerosis. It is therefore a model of
rapidly progressive glomerulonephritis in humans. TSA
ameliorates proliferative glomerulonephritis, long-term glo-
merulosclerosis, and proteinuria in this model [65]. Adria-
mycin induces a less proliferative glomerular disease in rats,
characterized by glomerular epithelial cell injury and pro-
gressive glomerulosclerosis, and is a model of human focal
segmental glomerulosclerosis (FSGS) [66]. Pre-treating
mice with VPA, a class I-selective HDACi, before adriamy-
cin injection ameliorated proteinuria as well as sclerotic
disease features, and preserved most features of podocyte
morphology [67]. Additionally, a course of VPA treatment
after adriamycin injection was able to improve proteinuria
and sclerosis compared to untreated controls. VPA treatment
reduced both proliferation in the glomerulus, as measured by
Ki67, and the expression of fibrotic markers, including TGF-
β1. This is consistent with data from diabetic nephropathy
Fig. 2 Summary of histone
deacetylases (HDAC) inhibitor
therapies used in renal injury
models. Several HDACis have
been found to attenuate fibrotic,
inflammatory, and proliferative
features of renal disease in
mammalian models. The
studies highlighted in this
review are organized here by
location of damage in the
nephron in the injury model
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models that implicate HDAC inhibition in the prevention of
fibrosis via TGF-β1 suppression. Thus, class I HDAC sup-
pression seems to have a therapeutic role in attenuating fibro-
sis in models of both diabetic nephropathy and FSGS.
Tubular and interstitial diseases
Tubulointerstitial fibrosis
Tubulointerstitial fibrosis is the common hallmark of chronic
kidney diseases from a variety of different causes. It is char-
acterized by renal tubular atrophy and progressive expansion
of the tubulointerstitial space with fibroblasts and by the
abnormal deposition of extracellular matrix components, in-
cluding type 1 collagen. The pathogenic mechanisms of tubu-
lointerstitial fibrosis are diverse and complex. However, key
elements include: 1) activation of TGF-β signaling in fibro-
blasts, promoting fibroblast proliferation and deposition of
abnormal extracellular matrix; and 2) infiltration with inflam-
matory cells which promote tissue injury and fibrosis by
releasing inflammatory cytokines and reactive oxygen spe-
cies. While therapeutic options in the clinic are limited,
HDACi is a promising treatment for targeting both the pro-
fibrotic and inflammatory pathogenic aspects of this condition
[61, 63].
To prevent renal fibrosis, researchers have focused their
efforts on elucidating the mechanisms of TGF-β signaling.
TSA treatment prevents TGF-β1-dependent responses in cul-
tured human renal tubule epithelial cells (RTECs) [57]. Cells
treated with TSA still demonstrated Smad protein phosphor-
ylation, which relays TGF-β1 signaling to the nucleus, indi-
cating that TSA blocks TGF-β1’s effects downstream of these
factors. Co-treatment of human RTECs with TGF-β1 and
TSA prevented TGF-β-induced apoptosis by blocking cas-
pase protein cleavage (also observed in an in vivomodel [68]).
This effect was mediated by inhibiting extracellular signal-
regulated kenase (ERK) activation. This latter finding is no-
table since recent studies have shown that the epidermal
growth factor receptor (EGFR), is required for sustained
TGF-β-dependent fibrosis in a mouse model of angiotensin
II-induced renal fibrosis [69]. Thus, this work proposes a dual
therapeutic role for HDAC inhibition in preventing tubular
interstitial fibrosis: (1) suppressing the pro-fibrotic effects of
TGF-β1, and (2) ameliorating renal tubular atrophy by pro-
tecting against tubular epithelial cell apoptosis.
Additional mechanisms have been proposed for attenuat-
ing tubular damage-mediated fibrosis through HDAC inhi-
bition. Pang et al. induced tubulointerstitial injury in mice
via unilateral urinary obstruction (UUO), and correlated a
decrease in fibrotic markers in TSA-treated kidneys [68].
This was associated with decreased levels of phosphorylated
STAT3. Since STAT3 has been implicated in the regulation
of tubulointerstitial fibrosis following UUO [70] and is a
known HDAC target, these findings suggest HDACi may
also decrease renal fibrosis by decreasing STAT3 expression
and signaling in this model of chronic kidney disease. Thus,
HDACis are likely contributing in multiple ways to exert
anti-fibrotic effects.
HDACis have also been implicated in the prevention of
inflammatory infiltration after renal damage. Following
UUO, there is an increase in both HDAC1 and HDAC2 in
the tubular epithelium. While treatment with TSA decreased
fibrosis scores, it also decreased macrophage infiltration and
expression of CSF-1, a secreted cytokine that promotes
proliferation and survival of monocyte/macrophages. Simi-
larly, TSA and VPA were able to attenuate TNF-α-induced
CSF-1 secretion by cultured renal tubular epithelial cells
[71]. Work by another group demonstrated that treatment
with FR276457, a hydroxamic acid derivative that inhibits
both class I and II HDACs, after UUO resulted in decreased
MCP-1 levels, a chemotactic cytokine that normally attracts
macrophages to the kidney shortly after UUO [72]. Howev-
er, the role of macrophages in acute and chronic kidney injury
is complex. It involves both the detrimental effects of early,
inflammatory M1 macrophages, and late, anti-inflammatory
M2 macrophages that also enhance epithelial regenerative
responses [73]. Therefore HDACis likely decrease pro-
inflammatory M1 macrophages early, and/or promote expan-
sion of anti-inflammatory and pro-regenerative M2 macro-
phages later in the course of disease.
Cystic disorders
Polycystic kidney disease (PKD) is characterized by the
development of fluid-filled cysts, lined by epithelial cells,
in the renal parenchyma. In humans, autosomal dominant
PKD is caused primarily by mutations in PKD1 or PKD2
[12, 74]. These genes encode polycystins, proteins that
coordinate calcium flux in association with primary cilia
via mechanisms not well understood [75]. This coordination
may serve as a sensor for epithelial proliferation since muta-
tions in either gene lead to excessive proliferation and cyst
formation [12, 74, 75]. Currently, therapies are limited and
the majority of PKD progresses to end stage renal disease
[74, 76, 77]. While most therapeutic strategies aim to inhibit
either mTOR signaling or the renin-angiotensin system, no
single-drug regimen has been identified that successfully
inhibits cyst formation [77]. As the mechanisms of cyst
formation in PKD pathogenesis are beginning to unfold,
HDACs have emerged as a novel therapeutic target.
Using zebrafish as a model system, chemical screens
identified TSA as a compound that could partially suppress
phenotypes correlated with cyst formation in larval PKD
models. Both TSA and VPAwere able to retard cyst forma-
tion in pkd2 mutant zebrafish larvae, and knockdown of
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hdac1 in larvae suppressed the pkd2mutant phenotype. Inter-
estingly, these observations were translatable to a mammalian
system. While VPA treatment in Pkd1 knockout mice slightly
decreased cyst formation [74], TSA reduced cyst formation in
Pkd1 mutant embryos [76]. These data point to the potential
for class I HDACis in the further study of PKD etiology.
Mechanistically, p53 deacetylation may be the link be-
tween HDACs and cyst formation. Not only is p53 a direct
target of HDAC1 [12], but it can also bind the promoter of
PKD1, resulting in transcriptional repression [78]. Interest-
ingly, inhibiting both class I and II HDACs with TSA
alleviated PKD1 transcriptional repression in vitro [78].
Further experiments are warranted to determine specifically
whether class I or class II HDACs are involved in this
transcriptional regulation since there is also evidence impli-
cating class II HDACs in cyst formation. Using an in vitro
assay with polycystin 1 mutant cells, it was shown that
HDAC5 is phosphorylated and exported from the nucleus
in response to shear stress, allowing it to activate down-
stream targets [75]. Furthermore, it was demonstrated that
cystic kidney phenotypes were reduced in Hdac5, Pkd2
double null mouse embryos, and that TSA administration
decreased cyst formation in Pkd2 mutant embryos.
An alternative mechanism for HDACi attenuation of cyst
formation involves cell cycle regulation via p21 and Rb-E2F1
signaling. Pkd1 mutant cells enter S phase more frequently
than wild-type cells, leading to enhanced proliferation and
cyst formation. TSA treatment decreased S-phase entry in
these cells in vitro through a mechanism involving reduced
Id2 levels and increased p21 levels. This work implicates
HDAC inhibition in cell cycle regulation as a mechanism
for decreasing epithelial proliferation and attenuating cyst
formation [76, 79].
HDACi in kidney injury
In addition to anti-fibrotic and anti-inflammatory effects,
there is also evidence that epigenetic modulation through
HDACis can promote regeneration after tissue injury by
reactivating the expression of signaling machinery normally
required during kidney organogenesis. This “regeneration
recapitulates development” paradigm underlies the regenera-
tive capacity of several mammalian organs, and we are only
beginning to understand the extent to which this mechanism
plays a role in kidney regeneration.
Marumo et al. [80] observed that exposure to transient
renal ischemia resulted in histone hypoacetylation in mouse
proximal tubule epithelial cells. This led them to investigate
whether HDACs played a role in modulating the kidney’s
response to ischemic injury. In an in vitro model, recovery
after reperfusion was associated with decreased levels of
HDAC5, and knockdown of HDACs 1, 2, or 5 induced
expression of BMP7. In vivo, fewer HDAC5-positive cells
were observed in proximal tubules after reperfusion, which
correlated with histone hyperacetylation and induction of
BMP7 expression.
These experiments suggest that proximal tubule recovery
following renal ischemia may be modulated by HDAC
activity, perhaps through the reactivation of BMP7. While
BMP7 is expressed in the developing mammalian kidney, it
is absent in the proximal tubules of the adult kidney. Since
BMP signaling is reactivated post-renal ischemia [81], and
exogenous BMP7 treatment is therapeutic in rodent kidney
injury models [82–84], the “regeneration recapitulates de-
velopment” paradigm characteristic of other organs may
also apply to the kidney. Importantly, these changes in
histone acetylation status and gene expression occur during
the recovery phase after reperfusion, implying that treatment
with an HDACi may be a useful therapy after injury has
occurred in a hospital setting.
Accordingly, treatment with TSA prevented proteinuria
and BUN elevation in NTN mice [65]. This global attenu-
ation of renal injury was associated with activation of BMP7
expression in an uncharacterized side population of cells
identified by flow cytometry. Although controversial, some
believe this side population may constitute a population of
intrarenal stem cells [85, 86]. Since TSA treatment did not
increase BMP7 expression in other renal cells, this population
may serve as a source of BMP7 to promote renal regeneration.
This suggests that pharmaceutical HDACi therapy may have
the potential to stimulate the BMP pathway, or other develop-
mental pathways, and promote regeneration, thus ameliorat-
ing kidney injury.
HDAC inhibitors and renal carcinoma
The critical role that HDACs play in cancer progression has
been appreciated for some time, since changes in HDAC
expression or inappropriate recruitment of these enzymes
has been observed in a number of human cancers [17]. Class
I HDACs, specifically HDACs 1 and 2, are highly expressed
in renal cell carcinoma (RCC), making these particularly
interesting therapeutic targets [87]. Because of this,
researchers have focused much of their efforts on designing
effective treatments to inhibit HDACs. This is clearly evi-
dent by the number of treatments that are currently in
clinical trials (Table 1) [88]. The mechanisms of action vary
for these inhibitors, although the identities of the “key”
targets are still not completely clear [89]. Regardless, HDA-
Cis have been shown to induce growth arrest, apoptosis, and
differentiation in a number of tumor cell lines as well as in
mouse tumor models. They are also important for inhibiting
tumor angiogenesis, which is normally critical for growth
and progression of solid tumors [90, 91].
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In RCC, HDACis play an important role in promoting
both cell cycle arrest and apoptosis. Treatment of RCC cell
lines with VPA inhibits proliferation and results in increased
levels of p21, a cyclin-dependent kinase inhibitor [92].
While HDACis have been touted for their ability to promote
G1 arrest, primarily through the up-regulation of p21 [17],
these small molecules are also capable of inducing arrest at
the G2-M transition [89]. This G2-M arrest has been docu-
mented in RCC cell lines treated with the HDACi LBH589
(Panobinostat) as well as the novel γ–lactam-based HDACi
KBH-A145 [93, 94]. Mechanistically, LBH589 treatment
reduces the protein levels of both Aurora A and B kinases,
which normally play important roles during mitosis, and this
effect is mediated specifically through the inhibition of
HDAC3 and HDAC6 [93]. Since the levels of both Aurora
A and B kinases are significantly higher in tumors taken
from RCC patients, the use of HDACis as potential thera-
pies for RCC is certainly supported.
Currently, it appears that combinatorial therapy involving
HDACis holds the most promise for treating RCC (Table 1),
and there have been a number of studies utilizing this
approach. First, combinatorial therapy enhances anti-
proliferative effects. VPA, in combination with low-dosed
interferon-α, is more effective at reducing overall HDAC
activity as well as inhibiting cell proliferation in RCC cell
lines compared with single-agent treatments [92]. Addition-
ally, this combinatorial effect is seen when VPA is used in
conjunction with AEE788, a receptor tyrosine kinase inhib-
itor, or RAD001, an inhibitor of mTOR [95, 96]. Likewise,
the combination of SAHA with either the protease inhibitor
ritonavir or the topoisomerase I inhibitor topotecan results in
more potent inhibition of HDACs, promotion of pRb dephos-
phorylation, and reduced proliferation [97, 98].
Second, combination therapy involving HDACis appears
to attenuate the levels of hypoxia inducible factors (HIFs)
which are often dysregulated in clear cell RCC due to the
inactivation of the tumor suppressor gene, von Hippel-Lindau
(VHL) [99]. This effect can be augmented when HDACis,
particularly LBH589, are used in conjunction with rapamycin,
an inhibitor of the mammalian target of rapamycin [100].
Since HIFs are pro-angiogenic transcription factors that sup-
port tumor growth by promoting vascularization, these studies
not only implicate HDAC involvement in the upregulation of
HIFs during tumor growth, but they also suggest a role for
HDACis in RCC treatment.
Finally, HDACis have been used in combination with reti-
noic acid (RA) to promote cancer cell differentiation, which is
compromised during cancer development and serves as a
hallmark of the disease [89]. RA is a diffusible factor derived
from vitamin A that has been used for the treatment of a
number of cancers. However, some renal malignancies have
shown resistance to this therapy [101, 102]. Data from RCC
cell lines suggest that this retinoid-resistance is due to loss of
RARβ2 expression [103]. Treatment with MS-275 (Entinostat)
results in hyperacetylation of the RARβ2 promoter and re-
expression of this gene, restoring sensitivity of these lines to
retinoids. When MS-275 is combined with 13-cis-retinoic acid
(cRA), there is a significant inhibition of RCC tumor growth in
mouse xenografts. Similar results have been obtained with
TSA and all-trans retinoic acid [104]. This combinatorial
treatment of HDACi and cRA has been used in phase I clinical
trials for patients with advanced solid tumors, including renal
malignancies [105]. Taken together, these data suggest the
HDAC inhibition coupled with additional therapies may be
the most effective method of treatment for RCC.
Towards the future
Since HDACis ameliorate AKI-mediated damage, promote
regenerative responses, and decrease scarring in kidney
disease models, the use of these compounds as renal injury
therapeutics is now in the realm of possibility. However, the
mechanism underlying how HDACis affect renal tubular
epithelial cells during regeneration is unclear. In a post-
damage environment, regenerating proximal tubular epithe-
lial cells proliferate and express genetic markers normally
associated with the early embryonic renal epithelia (in the
pre-tubular aggregates and renal vesicles). These markers,
which include Pax2, Wnt4, Lhx1 and components of the
Notch signaling pathway [81, 106–108], normally appear
within the first 24 h following injury and are subsequently
lost as the cells undergo epithelial differentiation. Possibly,
by promoting a more open chromatin environment, HDACis
may contribute to the re-expression of these embryonic
markers and thus regeneration, although the exact mecha-
nism regulating embryonic gene reactivation following kid-
ney damage is currently unknown. While work to date
provides correlative evidence, a direct link between HDACi
treatment and embryonic gene reactivation has yet to be
established. As mentioned in this review, recent studies have
demonstrated a reversible reduction in HDAC activity and
increased histone acetylation (K9 acetyl-histone H3) in
regenerating proximal tubular epithelial cells following renal
ischemia [80]. As epigenetic regulation of gene expression
during development is in part regulated by histone acetylation
[8], these findings suggest that alterations in HDAC activity
could mediate the epigenetic reprogramming of regenerating
tubular cells to a more primitive embryonic epithelial state.
Interestingly, work in an iPS reprogramming study demon-
strated that VPA could drive mouse embryonic fibroblasts to a
more primitive, embryonic stem cell-like state [109]. There-
fore, understanding howHDACis influence the transcriptional
profile of renal tubular epithelial cells during regeneration is
essential to understanding how these compounds can be used
as AKI therapeutics.
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To successfully develop new therapeutic HDACis, an
appreciation for the balance between potency and toxicity
as well as the myriad of substrate targets is required. More-
over, while preliminary studies indicate that these agents have
beneficial effects in diverse disease processes (Fig. 2), the
mechanisms by which they mediate these effects need to be
precisely defined in order to improve drug design and target-
ing. Therefore, simply designing the most effective pan-
HDACi, that works at the lowest concentration, will likely
result in a poor candidate for drug development. Similarly,
pursuing the “nanomolar rule” could either result in rejecting
effective compounds, which could have been the case with
SAHA [17], or selecting those that are highly toxic and
produce off-target effects in animal models [110]. Likely, the
most pressing hurdle to overcome in drug development is
assessing the toxicity associated with certain categories of
HDACis. The hydroxamic acid class of HDACis has been
shown to be relatively toxic in the kidney. SAHA induces
apoptosis in 35 % of a population of cultured rat renal prox-
imal tubule cells [31], and in cultured mouse proximal tubule
cells, TSA treatment results in the upregulation of targets
linked to ROS generation [32]. In general, hydroxamic acids
are subject to sulfation, which leads to the buildup of highly
reactive, toxic sulfate metabolites of the hydroxy group [33].
Although TSA is widely used for research purposes, its ther-
apeutic potential may be limited and, based on these studies, it
may be warranted to monitor renal function in patients under-
going hydroxamic acid HDACi therapy. Decreasing associat-
ed HDACi toxicities may likely include the use of class-
specific HDACis, rather than pan-inhibitors like SAHA and
romidepsin [2]. However, data to support this claim is cur-
rently limited, and there is evidence that a class I inhibitor,
MS-275, shows a similar toxicity profile in cancer patients to
the more broad-spectrum inhibitors [111]. Therefore, devel-
oping the ultimate therapeutic HDACi may require a combi-
nation of class specificity and non-toxic metabolic products.
Additionally, the development of novel HDACis depends
on a thorough understanding of the molecular mechanism of
action for each compound, including the interaction between
the HDACi and the target HDAC as well as the specific
response this interaction creates [112]. This will allow for the
effective design of drugs that are capable of distinguishing
within and between HDAC classes. As described above, prog-
ress has been made in this pursuit since it is now appreciated
that HDACs function as both corepressors and coactivators,
and these effects appear to be context-dependent. These
enzymes are capable of targeting many non-histone proteins
and, in some instances, participating directly in gene activation
[4, 5]. Therefore, the molecular mechanism of action can vary
for individual inhibitors which is likely due to the fact that the
identity of the main target(s) is still not completely clear [89].
Defining these targets will hopefully guide the development
and effective application of isoform-selective HDACis. The
prowess of HDACis as successful therapeutics in a wide array
of clinical applications, including the treatment of cancer, has
been clearly demonstrated. Thus, the stage has been set for
their future use in the treatment of AKI.
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